Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662714 | 1.00 | SLC5A2 (1.00) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL9973926 | 1.00 | SLC5A2 (1.00) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL147718 | 1.00 | SLC5A2 (1.00) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12426275 | 0.90 | SLC5A2 (0.82) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12426002 | 0.88 | SLC5A2 (0.78) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12426003 | 0.87 | SLC5A2 (0.77) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL14049027 | 0.87 | SLC5A2 (0.77) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL1853497 | 0.87 | SLC5A2 (0.77) | SLC5A2 | |
| SCHEMBL12426045 | 0.86 | SLC5A2 (0.75) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 | |
| SCHEMBL12426273 | 0.85 | SLC5A2 (0.74) | SLC5A2CHRM1SLC5A1ADRA1ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2514756-B1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7943788-B2 | Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885CHRM1 3468/4885SLC5A1 13/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885CHRM1 3468/4885SLC5A1 13/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | SLC5A2 5/4885CHRM1 3468/4885SLC5A1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.